Articole cu mandate pentru acces public - Rom LeidnerAflați mai multe
Disponibile undeva: 31
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
T Duhen, R Duhen, R Montler, J Moses, T Moudgil, NF De Miranda, ...
Nature communications 9 (1), 2724, 2018
Mandate: US Department of Energy, US National Institutes of Health
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
EEW Cohen, RB Bell, CB Bifulco, B Burtness, ML Gillison, KJ Harrington, ...
Journal for immunotherapy of cancer 7, 1-31, 2019
Mandate: US National Institutes of Health, Cancer Research UK, National Institute for …
Neoantigen T-cell receptor gene therapy in pancreatic cancer
R Leidner, N Sanjuan Silva, H Huang, D Sprott, C Zheng, YP Shih, ...
New England Journal of Medicine 386 (22), 2112-2119, 2022
Mandate: US National Institutes of Health
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells
Z Zhang, S Kobayashi, AC Borczuk, RS Leidner, T LaFramboise, ...
Carcinogenesis 31 (4), 577-586, 2010
Mandate: US National Institutes of Health
Multiparametric immune profiling in HPV–oral squamous cell cancer
Z Feng, D Bethmann, M Kappler, C Ballesteros-Merino, A Eckert, RB Bell, ...
JCI insight 2 (14), e93652, 2017
Mandate: US National Institutes of Health
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
RL Ferris, WC Spanos, R Leidner, A Gonçalves, UM Martens, C Kyi, ...
Journal for immunotherapy of cancer 9 (6), e002568, 2021
Mandate: US National Institutes of Health
Dampening enthusiasm for circulating microRNA in breast cancer
RS Leidner, L Li, CL Thompson
PloS one 8 (3), e57841, 2013
Mandate: US National Institutes of Health
Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell …
R Leidner, M Crittenden, K Young, H Xiao, Y Wu, MA Couey, AA Patel, ...
Journal for immunotherapy of cancer 9 (5), e002485, 2021
Mandate: US National Institutes of Health
Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma
RJ Kelly, J Lee, YJ Bang, K Almhanna, M Blum-Murphy, DVT Catenacci, ...
Clinical Cancer Research 26 (4), 846-854, 2020
Mandate: US National Institutes of Health
The microRNAs, MiR‐31 and MiR‐375, as candidate markers in Barrett's esophageal carcinogenesis
RS Leidner, L Ravi, P Leahy, Y Chen, B Bednarchik, M Streppel, M Canto, ...
Genes, Chromosomes and Cancer 51 (5), 473-479, 2012
Mandate: US National Institutes of Health
Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma
AM Kaz, Y Luo, S Dzieciatkowski, A Chak, JE Willis, MP Upton, ...
Genes, Chromosomes and Cancer 51 (4), 384-393, 2012
Mandate: US National Institutes of Health
First-in-human study of cemiplimab alone or in combination with radiotherapy and/or low-dose cyclophosphamide in patients with advanced malignancies
KP Papadopoulos, ML Johnson, AC Lockhart, K Moore, GS Falchook, ...
Clinical Cancer Research 26 (5), 1025-1033, 2020
Mandate: US National Institutes of Health
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
BD Curti, Y Koguchi, RS Leidner, AS Rolig, ER Sturgill, Z Sun, Y Wu, ...
Journal for immunotherapy of cancer 9 (4), e002371, 2021
Mandate: US National Institutes of Health
DNA methylation profiling in Barrett’s esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses
AM Kaz, CJ Wong, Y Luo, JB Virgin, MK Washington, JE Willis, ...
Epigenetics 6 (12), 1403-1412, 2011
Mandate: US National Institutes of Health
Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens
ML Morton, X Bai, CR Merry, PA Linden, AM Khalil, RS Leidner, ...
Lung cancer 85 (1), 31-39, 2014
Mandate: US National Institutes of Health
Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies
H Moinova, RS Leidner, L Ravi, J Lutterbaugh, JS Barnholtz-Sloan, ...
Cancer epidemiology, biomarkers & prevention 21 (4), 594-600, 2012
Mandate: US National Institutes of Health
STING expression and response to treatment with STING ligands in premalignant and malignant disease
JR Baird, Z Feng, HD Xiao, D Friedman, B Cottam, BA Fox, G Kramer, ...
PLoS One 12 (11), e0187532, 2017
Mandate: US National Institutes of Health
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
K Conlon, DC Watson, TA Waldmann, A Valentin, C Bergamaschi, ...
Journal for immunotherapy of cancer 9 (11), e003388, 2021
Mandate: US National Institutes of Health
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer
S Napolitano, M Woods, HM Lee, V De Falco, G Martini, CM Della Corte, ...
Clinical Cancer Research 29 (12), 2299-2309, 2023
Mandate: US National Institutes of Health, Government of Italy, Cancer Prevention …
EGFR molecular testing in African-American non-small cell lung cancer patients-a review of discrepant data
BT Clifford, P Fu, NA Pennell, B Halmos, RS Leidner
Translational Lung Cancer Research 2 (3), 251, 2013
Mandate: US National Institutes of Health
Informațiile despre publicații și finanțare sunt alese automat de un program informatic